<DOC>
	<DOC>NCT00319917</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy on joint damage and safety in RA patients treated with DMARDs in a double blind, placebo controlled study.</brief_summary>
	<brief_title>A Double Blind Placebo Controlled Study to Assess the Efficacy on Joint Damage in RA Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Clinically diagnosed as rheumatoid arthritis by the revised ACR criteria Those who have been treated with an adequate stable dose of either methotrexate, salazosulfapyridine or bucillamine Those who have at least one erosion on Xray of hands, wrists or feet Those who have been treated with any biologic drugs or leflunomide Those who meet Class 4 with the Steinbrocker functional classification</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Tacrolimus anhydrous</keyword>
</DOC>